CBIS.OB – Can they be successful in Getting FDA approval for Cannabanoid Pharmaceuticals ?
Sativex
Developed by GW Pharmaceuticals, Sativex is a whole plant medicinal cannabis extract indicated for relief of symptoms of multiple sclerosis (MS) and for treatment of severe neuropathic-related cancer pain.
Bayer has secured exclusive rights to market Sativex in the UK with the option to extend this to other countries in Europe and countries such as Canada, where Sativex received regulatory approval in 2005 for treatment of neuropathic pain associated with MS.
Apparently The FDA hesitates on FDA approval for Smoke Inhaled Intake of THC and Marijuana derived Cannabanoids.
However as in GW Pharmaceuticals example FDA approval can be garnered if the Cannabanoids are ingested by alternative means.
Thus the CBIS.OB Plan of Operation and Methods of Delivery
Press Release
Source: Cannabis Science Inc.
On Thursday June 18, 2009, 12:06 pm EDT
Cannabis science, inc.
SAN FRANCISCO--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, announced today that patent filings are expected for two of its key innovations. “The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two,” Dr. Mary J. Ruwart, Vice President, Research & Development explained. “A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to ‘invasion’ by a competing company.”
Related Quotes
Symbol
Price
Change
CBIS.OB
0.07
0.00
Cannabis Science CEO, Steve Kubby, is the inventor who will assign both of his patents to Cannabis Science. “Our new manufacturing process allows for the rapid and uniform harvesting of cannabis ‘trichomes,’ the part of the plant containing the active ingredient, THC,” Kubby told potential investors today. “Just as the cotton gin made cotton harvesting economically feasible, our innovative process will revolutionize trichome harvesting.”
“Having a creative mind like Steve Kubby’s at the helm gives us a competitive advantage,” Dr. Robert Melamede, Chief Scientific Officer commented. “The new manufacturing process is only the tip of the proverbial iceberg. The unique drug delivery system he has designed enhances the stability and uniform absorption of the active ingredient. We expect our first product to outshine the competition with rapid---and prolonged---blood levels of THC.”
Cannabis Science management has authorized expenditures for patents; the two described above will be the company’s first official filings. “Naturally, Cannabis Science will use both of its discoveries for its own drug production,” Chief Financial Officer, Richard Cowan said. “However, other firms will likely want to license these inventions for their own use as well. Cannabis Science will be able to supply other companies with superior trichome preparations or provide our unique drug delivery systems for other pharmaceutical preparations. The entire industry, the American public, and, of course, Cannabis Science and its investors, will reap the benefits.” |
